Mona Chitre, PharmD, CGP: Every social determinant of health has the impact and the potential to exacerbate MDD [major depressive disorder]. MDD and social determinants of health have a unique relationship. Social determinants of health can trigger mental health disorders, and mental health disorders can cause someone to make poor life decisions that trigger social determinants of health.
Let’s talk about social determinants of health. I often say it’s anything in your environment that can enable you to thrive, be well, or see a positive future. In the mental health arena, some pop up frequently. In no particular order, one is safe housing. Is there a safe housing option for our members? Are they in a safe community? Are they free of trauma and stress? Food and transportation are some basics. Do they know where their next meal is going to come from? Do they have access to a physician’s office or a pharmacy? Income level is another. Income level has many triggers toward health care disparities in general. It affects health care literacy, access to care, and access to treatment. Is their job secure? Is it a toxic environment? Is it safe? Family relationships [are another factor]. That’s just to name a few. Is there a family support group? Any social determinant of health can trigger a mental health challenge, a mental health crisis, or a mental health disorder.
Jay Weaver, PharmD, MPH: I have to agree with Dr Chitre. Most of the things she outlined were spot on. The only thing I’d add would be some of the nutritional challenges. We’re coming to understand that there’s a link between the foods that we eat and have access to and our sense of well-being. Things like high-calorie foods and high-carbohydrate foods are typically less expensive than higher-quality foods. We also know that the amounts of sugar and other things in those foods can affect our mental well-being. Sometimes food insecurity plays into major depressive disorder in ways that we don’t fully understand.
Transcript edited for clarity.
Social Determinants of Health in MDD: Part 2
Key social determinants of health impacting MDD are discussed by expert payer panelists.
EP: 1.Unmet Needs in Treatment of MDD
EP: 2.MDD Treatment Landscape
EP: 3.Potential Consequences of Recurrent or Poorly Controlled MDD
EP: 4.Burden of Treatment Failure in MDD
EP: 5.Importance of Early Effective Treatment of MDD
EP: 6.Evaluating MDD Treatment Attributes
EP: 7.Considerations for Newly Launched MDD Treatments
EP: 8.Healthcare Disparities Within Major Depressive Disorder
EP: 9.MDD Treatment Disparities Across Patient Populations
EP: 10.Social Determinants of Health in MDD
EP: 11.Impact of COVID-19 on Demand for Mental Health Services
EP: 12.Health Care Disparities Within Major Depressive Disorder (MDD)
EP: 13.MDD Treatment Disparities Across Patient Populations: Part 2
EP: 14.Social Determinants of Health in MDD: Part 2
EP: 15.Population Health Approach in MDD
EP: 16.Factors Affecting MDD Treatment Adherence
EP: 17.Supporting Adherence for Patients with MDD
EP: 18.Aligning MDD Treatment Goals for Payers and Patients
EP: 19.The Impact of Early Effective Treatment in MDD
EP: 20.Key Contributors to Long-term Outcomes for Patients With MDD
Mona Chitre, PharmD, CGP: Every social determinant of health has the impact and the potential to exacerbate MDD [major depressive disorder]. MDD and social determinants of health have a unique relationship. Social determinants of health can trigger mental health disorders, and mental health disorders can cause someone to make poor life decisions that trigger social determinants of health.
Let’s talk about social determinants of health. I often say it’s anything in your environment that can enable you to thrive, be well, or see a positive future. In the mental health arena, some pop up frequently. In no particular order, one is safe housing. Is there a safe housing option for our members? Are they in a safe community? Are they free of trauma and stress? Food and transportation are some basics. Do they know where their next meal is going to come from? Do they have access to a physician’s office or a pharmacy? Income level is another. Income level has many triggers toward health care disparities in general. It affects health care literacy, access to care, and access to treatment. Is their job secure? Is it a toxic environment? Is it safe? Family relationships [are another factor]. That’s just to name a few. Is there a family support group? Any social determinant of health can trigger a mental health challenge, a mental health crisis, or a mental health disorder.
Jay Weaver, PharmD, MPH: I have to agree with Dr Chitre. Most of the things she outlined were spot on. The only thing I’d add would be some of the nutritional challenges. We’re coming to understand that there’s a link between the foods that we eat and have access to and our sense of well-being. Things like high-calorie foods and high-carbohydrate foods are typically less expensive than higher-quality foods. We also know that the amounts of sugar and other things in those foods can affect our mental well-being. Sometimes food insecurity plays into major depressive disorder in ways that we don’t fully understand.
Transcript edited for clarity.
US Health Care Disparities in Immunology Biologics Access: A Systematic Review
August 1st 2025This article presents a systematic review of US health care disparities in biologics access across immunology (ie, rheumatology, dermatology, and gastroenterology) and a call to action.
Read More
High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management
July 24th 2025This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.
Listen
Reassessing Antidepressant Efficacy: A Meta-Analysis of Control Group Outcomes in SSRI, Psilocybin, and Esketamine Trials
July 31st 2025A meta-analysis showed that control group outcomes in psilocybin trials for depression were significantly weaker than those in selective serotonin reuptake inhibitor (SSRI) and esketamine trials, suggesting that psilocybin’s large observed treatment effects may be inflated by methodological factors such as functional unblinding and expectancy bias.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
High Adenoma Detection Rates Linked to Lower CRC Rates, Worse Survival
July 31st 2025In a large fecal immunochemical test-based screening program, high adenoma detection rates lowered interval colorectal cancer (CRC) incidence and mortality, but not CRC-specific survival.
Read More
US Health Care Disparities in Immunology Biologics Access: A Systematic Review
August 1st 2025This article presents a systematic review of US health care disparities in biologics access across immunology (ie, rheumatology, dermatology, and gastroenterology) and a call to action.
Read More
High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management
July 24th 2025This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.
Listen
Reassessing Antidepressant Efficacy: A Meta-Analysis of Control Group Outcomes in SSRI, Psilocybin, and Esketamine Trials
July 31st 2025A meta-analysis showed that control group outcomes in psilocybin trials for depression were significantly weaker than those in selective serotonin reuptake inhibitor (SSRI) and esketamine trials, suggesting that psilocybin’s large observed treatment effects may be inflated by methodological factors such as functional unblinding and expectancy bias.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
High Adenoma Detection Rates Linked to Lower CRC Rates, Worse Survival
July 31st 2025In a large fecal immunochemical test-based screening program, high adenoma detection rates lowered interval colorectal cancer (CRC) incidence and mortality, but not CRC-specific survival.
Read More